Opendata, web and dolomites

PROGSY SIGNED

Prosaposin and GPR37 in synucleinopathies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROGSY project word cloud

Explore the words cloud of the PROGSY project. It provides you a very rough idea of what is the project "PROGSY" about.

prosaposin    normal    hallmark    agonists    versus    lbs    atomic    propensity    progression    cue    intracellular    advancements    structures    bodies    gpr37    label    anti    secreted    autopsy    insights    tracers    synuclein    gpcrs    virally    dopamine    pet    neurotrophic    gpcr    grossly    stress    delineate    enzyme    neurotoxic    regulates    neurotoxicity    mice    disease    accumulation    dopaminergic    lysosomal    survival    dj    examine    gba    contributions    pd    plasma    ligands    lrrk2    single    suggest    trafficking    initiate    saposin    pathological    neuroprotection    correlation    consistently    prosaptide    function    relative    acute    cellular    unexpectedly    underlying    breakthrough    membraneous    agonism    interference    pathogenic    gene    released    treatment    dimer    membrane    alpha    drug    cgpr37ko    incl    multimerization    transduced    fluorescence    aggregated    technological    psap    neuroprotective    parkin    constituent    diagnosis    prosaptides    aggregation    co    injury    molecule    mechanistic    located    modeling    spectroscopy    neurons    exceptional    hypothesize    protein    receptor    parkinson    linked    synucleinopathies    fragment    lewy    pivotal   

Project "PROGSY" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 1˙950˙033 €
 EC max contribution 1˙950˙033 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-CoG
 Funding Scheme ERC-COG
 Starting year 2015
 Duration (year-month-day) from 2015-08-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 1˙950˙033.00

Map

 Project objective

The next breakthrough in the treatment of synucleinopathies, incl Parkinson´s disease (PD), will be aimed at interference of disease progression based on insights into the underlying pathogenic process. The pathological hallmark of PD are Lewy bodies (LBs), in which α-synuclein is the major constituent together with other PD-linked gene products (DJ-1, LRRK2, parkin, and GBA) and aggregated GPR37. GPR37 is exceptional among GPCRs having a high propensity for intracellular receptor accumulation and aggregation leading to neurotoxicity. However, unexpectedly, our results suggest that GPR37 is neuroprotective in dopaminergic when located at the plasma membrane. Consistently, prosaposin (PSAP), and its neurotrophic fragment prosaptide, were recently identified as agonists at GPR37. PSAP is a neuroprotective protein that regulates intracellular lysosomal enzyme function, with saposin C being a co-factor of GBA. In addition, we hypothesize that PSAP is secreted following cellular stress and, via membraneous GPR37, cue dopamine neurons to initiate survival pathways. Pivotal to this programme is modeling and analysis of the atomic structures of GPR37 in complex with prosaptide, which will grossly facilitate mechanistic understanding and drug development with potential use in diagnosis and treatment. Novel applications and technological advancements of fluorescence correlation spectroscopy will be implemented for single molecule trafficking of GPR37 and its ligands and will examine whether GPCR multimerization beyond dimer formation may be neurotoxic. Normal and cGPR37KO mice will be virally transduced by α-synuclein to delineate in the relative contributions of improved lysosomal function versus GPR37 agonism for neuroprotection by prosaptides. Evolving from the autopsy studies that anti–GPR37 label LBs and that prosaposin is released upon cellular injury, we will develop GPR37 ligands as PET tracers for LBs in synucleinopathies.

 Publications

year authors and title journal last update
List of publications.
2020 Zhang X, Mantas I, Fridjonsdottir E, Andrén PE, Chergui K and Svenningsson P
Deficits in motor performance, neurotransmitters and synaptic plasticity in elderly and experimental parkinsonian mice lacking GPR37
published pages: 84-89, ISSN: 1663-4365, DOI: 10.3389/fnagi
Frontiers in Aging Neuroscience 2020.00084 2020-04-01
2017 Cyril Monnot, Xiaoqun Zhang, Sahar Nikkhou-Aski, Peter Damberg, Per Svenningsson
Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism
published pages: 11-20, ISSN: 0014-4886, DOI: 10.1016/j.expneurol.2017.02.014
Experimental Neurology 292 2019-06-07
2017 Leinartaité Lina, Svenningsson Per
Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease.
published pages: , ISSN: 0165-6147, DOI:
Trends in Pharmacological Sciences 2019-06-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROGSY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROGSY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CITISENSE (2019)

Evolving communication systems in response to altered sensory environments

Read More  

TORYD (2020)

TOpological many-body states with ultracold RYDberg atoms

Read More  

Mu-MASS (2019)

Muonium Laser Spectroscopy

Read More